Assessing the photometric redshift precision of the S-PLUS survey: The Stripe-82 as a test-case

Indexación ScopusIn this paper we present a thorough discussion about the photometric redshift (photo-z) performance of the Southern Photometric Local Universe Survey (S-PLUS). This survey combines a seven narrow +5 broad passband filter system, with a typical photometric-depth of r ∼ 21 AB. For this exercise, we utilize the Data Release 1 (DR1), corresponding to 336 deg2 from the Stripe-82 region. We rely on the BPZ2 code to compute our estimates, using a new library of SED models, which includes additional templates for quiescent galaxies. When compared to a spectroscopic redshift control sample of ∼100 k galaxies, we find a precision of σz <0.8 per cent, <2.0 per cent, or <3.0 per cent for galaxies with magnitudes r < 17, <19, and <21, respectively. A precision of 0.6 per cent is attained for galaxies with the highest Odds values. These estimates have a negligible bias and a fraction of catastrophic outliers inferior to 1 per cent. We identify a redshift window (i.e. 0.26 < z < 0.32) where our estimates double their precision, due to the simultaneous detection of two emission lines in two distinct narrow bands; representing a window opportunity to conduct statistical studies such as luminosity functions. We forecast a total of ∼2 M, ∼16 M and ∼32 M galaxies in the S-PLUS survey with a photo-z precision of σz <1.0 per cent, <2.0 per cent, and <2.5 per cent after observing 8000 deg2. We also derive redshift probability density functions, proving their reliability encoding redshift uncertainties and their potential recovering the n(z) of galaxies at z < 0.4, with an unprecedented precision for a photometric survey in the Southern hemisphere. © 2020 The Author(s)https://academic-oup-com.recursosbiblioteca.unab.cl/mnras/article/499/3/3884/585601

Posaconazole treatment of refractory eumycetoma and chromoblastomycosis Tratamento com posaconazol de casos de cromoblastomicose e micetoma maduromicótico resistentes a outros antifúngicos

Eumycetoma and chromoblastomycosis are chronic, disfiguring fungal infections of the subcutaneous tissue that rarely resolve spontaneously. Most patients do not achieve sustained long-term benefits from available treatments; therefore, new therapeutic options are needed. We evaluated the efficacy of posaconazole, a new extended-spectrum triazole antifungal agent, in 12 patients with eumycetoma or chromoblastomycosis refractory to existing antifungal therapies. Posaconazole 800 mg/d was given in divided doses for a maximum of 34 months. Complete or partial clinical response was considered a success; stable disease or failure was considered a nonsuccess. All 12 patients had proven infections refractory to standard therapy. Clinical success was reported for five of six patients with eumycetoma and five of six patients with chromoblastomycosis. Two patients were reported to have stable disease. As part of a treatment-use extension protocol, two patients with eumycetoma who initially had successful outcome were successfully retreated with posaconazole after a treatment hiatus of > 10 months. Posaconazole was well tolerated during long-term administration (up to 1015 d). Posaconazole therapy resulted in successful outcome in most patients with eumycetoma or chromoblastomycosis refractory to standard therapies, suggesting that posaconazole may be an important treatment option for these diseases.<br>Eumicetoma e cromoblastomicose são infecções fúngicas crônicas do tecido subcutâneo que evoluem com aspecto desfigurado, raramente involuindo espontaneamente. A maioria dos pacientes não apresenta melhora sustentada por longo tempo com os tratamentos disponíveis, sendo de grande importância as novas opções terapêuticas. A eficácia do posaconazol, um novo agente antifúngico de amplo espectro do grupo dos triazóis, foi estudada em 12 pacientes com eumicetoma ou cromoblastomicose refratária às terapêuticas antifúngicas disponíveis. Os pacientes receberam por no máximo 34 meses, doses divididas de 800 mg/dia de posaconazol. Resposta clínica parcial ou completa foi considerada como sucesso; doença estável ou falha terapêutica foi considerada como insucesso. Todos os 12 pacientes tinham infecções comprovadas ou prováveis, refratárias à terapêutica padrão preconizada. Sucesso clínico foi registrado em cinco de seis pacientes com eumicetoma e cinco de seis pacientes com cromoblastomicose. Em dois pacientes observou-se doença estável. Como parte do protocolo de extensão do tratamento, dois pacientes com eumicetoma que inicialmente tinham tido sucesso terapêutico e que após um intervalo maior de 10 meses apresentaram recidiva da micose, foram retratados com sucesso com posaconazol. Posaconazol foi bem tolerado durante o longo período de administração (até 1015 dias). A terapêutica com posaconazol foi seguida de sucesso na maioria dos pacientes com eumicetoma ou cromoblastomicose refratária à terapêutica padrão, sugerindo que tal droga possa ser uma importante opção no tratamento de tais doenças

Valuation and assessment of soil erosion costs

Soil is an essential natural resource for humans and an important part of the environment. However, soil is often used and managed inappropriately, causing its erosion and degradation, with concomitantly negative social, political and economic impacts. This study aimed to discuss sustainable development; and losses and problems caused by soil erosion, and to suggest a model for assessing erosion costs. The relevance of economic models for costing soil erosion is stressed. Based on an economic theory, it presents a procedure for assessing economic costs of soil erosion, centered on the on-site and off-site costs that are generated. The physical processes of soil erosion are described and their economic effects reviewed, drawing on theoretical and empirical sources. Limited data and information is available on the economic losses resulting from erosion, which hampers assessment and valuation